- Abstract
- Core Tip
- Article Highlights
- Full Article (PDF)
- Full Article (WORD)
- Full Article (HTML)
- Audio
- PubMed Central
- PubMed
- CrossRef
- Google Scholar
- Similar Articles (3)
- Timeline of Article Publication (0)
- Authors Evaluation (2)
- Article Quality Tracking (1)
- Reader Comments (1)
- Reference Citation Analysis (2)
-
Send to Friends (0)
Academic Content and Language Evaluation of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Checklist of Responsibilities for the Scientific Editor of This Article
Publishing Process of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2297)
All Articles published online
|
Publishing Process of This Article
|
Apr 15, 2022 (publication date) through Mar 30, 2023
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Xu YJ, Zhang P, Hu JL, Liang H, Zhu YY, Cui Y, Niu P, Xu M, Liu MY. Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio’s prediction on effectiveness. World J Gastrointest Oncol 2022; 14(4): 920-934 [PMID: 35582108 DOI: 10.4251/wjgo.v14.i4.920] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v14/i4/920.htm |
| Number | Citing Articles |
| 1 |
|